Stryker SYK Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| MedSurg and Neurotechnology: | $15.34B+13.8% | $15.19B+12.4% | $14.51B+8.4% | $14.03B+8.6% | $13.48B+7.2% | |
| Orthopaedics: | $9.93B+1.9% | $9.92B+9.3% | $9.87B+15.0% | $9.79B+15.6% | $9.74B+16.1% | |
| Segment operating income by Business | ||||||
| MedSurg and Neurotechnology: | $4.4B+12.5% | $4.46B+11.4% | $4.22B+7.6% | $4.08B+7.0% | $3.91B+6.1% | |
| Orthopaedics | $3.03B+4.9% | $3.03B+17.1% | $2.98B+25.9% | $2.93B+25.7% | $2.88B+27.5% | |
| Reclassification to: cost of sales by Business | ||||||
| MedSurg and Neurotechnology: | $5.83B+10.9% | $5.71B+7.4% | $5.5B+8.7% | $5.38B+8.5% | $5.26B+7.4% | |
| Orthopaedics | $2.76B+7.0% | $2.72B+13.2% | $2.67B+16.3% | $2.61B+13.6% | $2.58B+13.3% | |
| Additions and adjustments by Business | ||||||
| MedSurg and Neurotechnology | $2.38B+63.4% | $3.28B+284% | $2.67B+274% | $2.06B+258% | $1.46B+232% | |
| Orthopaedics | -$750K-100% | -$1M-100% | $74.25M-67.0% | $149.5M-0.3% | $224.75M+200% | |
| Selling, general and administrative expenses by Business | ||||||
| MedSurg and Neurotechnology: | $3.92B+18.9% | $3.85B+20.3% | $3.7B+21.3% | $3.51B+16.7% | $3.3B+11.3% | |
| Orthopaedics | $3.17B-3.7% | $3.21B+3.2% | $3.25B+8.6% | $3.27B+10.2% | $3.29B+11.6% | |
| Research, development and engineering expenses by Business | ||||||
| MedSurg and Neurotechnology: | $954M+19.7% | $931M+18.8% | $891M+15.8% | $849M+14.7% | $797M+10.5% | |
| Orthopaedics | $530M-6.0% | $542M+0.4% | $551M+3.4% | $555M+5.9% | $564M+9.5% | |
| D&A by Business | ||||||
| MedSurg and Neurotechnology: | $235M+16.3% | $228M+9.6% | $200M-7.1% | $204M+1.7% | $202M+6.5% | |
| Orthopaedics | $444M+2.8% | $432M-0.2% | $430M+2.0% | $431M+6.2% | $432M+8.7% | |
| Foreign exchange and other by Business | ||||||
| MedSurg and Neurotechnology | $35.75M-56.8% | $73M-15.1% | $76.25M+4.5% | $79.5M+32.5% | $82.75M+76.1% | |
| Orthopaedics | $56.75M+154% | $89M+152% | $24.25M+120% | -$40.5M+43.0% | -$105.25M-390% | |
| Capital Expenditures During Period by Business | ||||||
| MedSurg and Neurotechnology: | $245M-8.6% | $220M-20.3% | $293M+61.2% | $288M+65.0% | $268M+50.4% | |
| Orthopaedics | $288M+34.6% | $296M+28.7% | $228M+5.7% | $220M+9.7% | $214M+7.4% | |
| Net Sales by Product | ||||||
| Endoscopy | $3.81B+9.5% | $3.81B+12.3% | $3.67B+11.7% | $3.61B+13.0% | $3.48B+10.8% | |
| Hips | $1.88B+7.3% | $1.87B+9.4% | $1.83B+10.5% | $1.79B+12.2% | $1.75B+12.3% | |
| Instruments | $3.37B+12.2% | $3.29B+16.1% | $3.16B+13.9% | $3.08B+13.4% | $3.01B+14.0% | |
| Knees | $2.69B+7.6% | $2.66B+8.5% | $2.59B+8.5% | $2.54B+8.6% | $2.5B+8.8% | |
| Medical | $4.16B+5.8% | $4.2B+9.1% | $4.06B+8.3% | $4.02B+11.2% | $3.93B+10.9% | |
| Spine | $21M-97.0% | $185M-73.8% | $363M— | $529M— | $702M— | |
| Trauma and Extremities | $4.04B+11.5% | $3.95B+12.6% | $3.86B+14.4% | $3.75B+14.4% | $3.62B+12.9% | |
| Vascular | $2.08B+48.2% | $1.97B+50.6% | $1.77B+37.6% | $1.57B+24.1% | $1.4B+12.1% | |
| Net Sales by Geography | ||||||
| International | $6.23B+8.3% | $6.11B+8.1% | $5.94B+7.1% | $5.84B+8.3% | $5.75B+8.4% | |
| United States | $19.04B+9.0% | $19.01B+12.2% | $18.44B+12.2% | $17.98B+12.4% | $17.47B+11.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Stryker break its business down?
- Stryker (SYK) reports net sales by business across 2 parts — MedSurg and Neurotechnology: and Orthopaedics:. Each is extracted from the segment footnotes and tracked over time.
- Where does Stryker's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Stryker's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
